(firstQuint)Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma.

 This is multicenter, open label study to evaluate the safety and efficacy of bendamustine HCl in patients with indolent Non-hodgkin's lymphoma and relapsed after rituximab treatment.

 This injection will be given through i.

v.

 infusion in >= 60 minutes on days 1 and 2 of every 21-day treatment cycle.

 Patients will be treated for up to 8 cycles unless progressive disease or unacceptable toxicity take place.

 Patients will be followed for up to 1 year before evaluating progression free survival (PFS) and overall survival (OS).

.

 Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma@highlight

The purpose of this study is to determine whether bendamustine HCl for injection is safe and effective in the treatment of Rituximab refractory or relapsed B-cell indolent lymphoma.

